Institutional review board from Asan Medical Center issued an exemption to this study because of the use of collected existing data in such a manner that subjects cannot be identified, directly or through identifiers linked to subjects.
The data have been collected in such a manner that subjects cannot be identified, directly or through identifiers linked to the subjects.
Chart review and biological specimen studies: Research involving the collection or study of EXISTING data, documents, records, pathological specimens, or diagnostic specimens, if these sources are publicly available or if the information is recorded by the investigator in such a manner that subjects cannot be identified, directly or through identifiers linked to the subjects.
Therefore, participants cannot be identified, directly or through identifiers linked to the participants.
This is on condition that sources cannot be "identified directly or through identifiers linked to the samples and data" [ 1].
This study involved collection of existing data from patient records in such a manner that subjects cannot be identified, directly or through identifiers linked to the subjects.
Patients' personal information was recorded in such a manner that subjects cannot be identified directly or through identifiers linked to the subjects.
This study involved collection of existing data from patient records in such a manner that subjects could not be identified, directly or through identifiers linked to the subjects.
The data is not developed or reported in a way that subjects can be identified, directly or through identifiers linked to subjects.
Personal information concerning these samples had been recorded in such a manner that subjects could not be identified, directly or through identifiers according to the HIPAA rules.
As per the Code of Federal Regulations, Institutional Review Board review and approval is not needed for a study of this nature, as "…subjects cannot be identified, directly or through identifiers linked to the subjects…" (45 CFR 46 §46.101).
